Specialties
Reports that name this provider
- Hyperthermia Treatment in South Korea
- Published Phase 2 prospective trial (2022) of 60 locally advanced rectal cancer patients treated with mEHT-augmented thermoradiochemotherapy: 5-year overall survival 94.0%, 5-year disease-free survival 77.1%, loco-regional recurrence-free survival 96.4%, and 15% pathologic complete response at median follow-up of 58 months